[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"CivaTech Oncology\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100273800","phase-1-initial-feasibility-study-to-treat-borderline-resectable-pancreatic-cancer-with-a-planar-ldr-source-100273800",false,"NCT02843945","Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source","Initial Feasibility Study to Evaluate the Safety and Efficacy of the Permanently Implantable LDR CivaSheet® in Combination With External Beam Radiation in the Treatment of Pancreatic Cancer","Inclusion Criteria:\n\n* • Subject signed inform consent\n\n  * Age \\> 18 years\n  * Not pregnant or breast feeding\n  * Patient capable of undergoing anesthesia\n  * Patient selected to undergo Whipple procedure or distal pancreatectomy\n  * Patient does not have metastatic disease\n  * Patients will have close margins\n  * No prior radiation therapy to the region for separate cancer\n  * Confirmed diagnosis of borderline resectable or locally advanced pancreatic adenocarcinoma\n  * Patient Received neoadjuvant chemoradiation (4-10 weeks prior to surgery)\n  * Chemotherapy was administered for 2-6 cycles with any combination of the following agents:\n  * Gemcitabine + nb-paclitaxel\n  * FOLFIRINOX\n  * Neoadjuvant Chemoradiation was administered as IMRT or 3DCRT (up to 56 Gy), or SBRT (up to 36 Gy) with Pre-operative External beam dose (NCCN)\n  * up to 56 Gy (1.8-2.0 Gy per fractions) with concurrent gemcitabine, capecitabine, or infusional 5-fluorouracil\n\nExclusion Criteria:\n\n* Not surgical candidate\n* Any other invasive cancer in the past 5 years, except basal cell or squamous cell skin cancer\n* An IRE candidate (IRE is Percutaneous irreversible electroporation)\n* Recurrent or previously resected tumors\n* Documented History of Alcoholism and or drug abuse\n* Participant in other clinical trials","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.",[27],"Pancreatic Cancer",[29,30,31,32,33,34,35,36,37],"brachytherapy","CivaSheet","CivaTech","whipple","radiation","borderline resectable","locally advanced","Pd-103","intraoperative radiation","RECRUITING","2025-06-16",{"date":41,"type":42},"2025-06-17","ACTUAL",{"date":44,"type":42},"2017-05-31",{"date":46,"type":20},"2028-10-30",{"name":48,"class":49},"CivaTech Oncology","INDUSTRY",6,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100308072","phase-2-feasibility-study-to-treat-lung-cancer-with-the-permanently-implantable-ldr-civasheet-100308072","NCT03290534","Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®","Inclusion Criteria:\n\n* Subject signed inform consent\n* Suspected or proven non-small cell lung cancer (NSCLC) in the upper lobes of the left or right lung\n* Pre-operative criteria\n* Lung nodule suspicious for NSCLC\n* Mass ≤ 7 cm in maximum diameter by CT scan of the chest and upper abdomen\n* Clinical stage I or Clinical stage II\n* Not pregnant or nursing\n* Negative pregnancy test in premenopausal women\n* Fertile patients must use effective contraception\n* More than 5 years since prior invasive malignancy unless non melanoma skin cancer or in-situ cancer\n\nExclusion Criteria:\n\n\\-",{"count":58,"type":20},40,[24],"This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.",[62,63,64],"Lung Cancer","Lung Cancer Stage I","Lung Cancer Stage II",[66,67,29,30,36,48,68,69],"wedge resection","sublobar resection","lung cancer","lung","2025-04-02",{"date":72,"type":42},"2025-04-04",{"date":74,"type":42},"2019-03-13",{"date":76,"type":20},"2027-12",{"name":48,"class":49},1,""]